Show simple item record

dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorSamantas, E.en
dc.contributor.authorAthanasiades, A.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.creatorKosmidis, Paraskevas A.en
dc.creatorMylonakis, N.en
dc.creatorFountzilas, Georgeen
dc.creatorSamantas, E.en
dc.creatorAthanasiades, A.en
dc.creatorPavlidis, Nicholasen
dc.creatorSkarlos, Dimosthenis V.en
dc.description.abstractA recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the concentration-time curve of 7 in patients with advanced non-small cell lung cancer. In an effort to evaluate the dose-response relationship of paclitaxel with quality of life, we initiated a phase III prospective trial. Patients with inoperable non-small cell lung cancer were randomized into two groups. Group A received paclitaxel 175 mg/m2 plus carboplatin dosed to an area under the concentration-time curve of 6 every 3 weeks. Group a received the same regimen, with paclitaxel increased to 225 mg/m2. Since July 1996, 49 patients have entered the study, 29 in group A and 20 in group B. Patient and tumor characteristics were well distributed between both groups. In group A, 16 patients were evaluable, with one complete response, six partial responses, three stable disease, and six progressive disease. In group B, 12 patients were evaluable, with two partial responses, four stable disease, and six progressive disease. Treatment was well tolerated in both groups. More neurotoxicity and neutropenia were noticed with high-dose paclitaxel. There were no drug-related deaths. It is too early to draw definite conclusions regarding response and survival, but regarding toxicity, it seems that paclitaxel 225 mg/m2 plus carboplatin dosed to an area under the concentration-time curve of 6 is well tolerated without the use of growth factors. Although the results are premature, quality of life does not seem to be affected by the increased paclitaxel dose.en
dc.sourceSeminars in oncologyen
dc.subjectControlled studyen
dc.subjectAdvanced canceren
dc.subjectCancer combination chemotherapyen
dc.subjectCancer survivalen
dc.subjectDrug responseen
dc.subjectPriority journalen
dc.subjectClinical articleen
dc.subjectClinical trialen
dc.subjectControlled clinical trialen
dc.subjectPhase 3 clinical trialen
dc.subjectProspective studyen
dc.subjectRandomized controlled trialen
dc.subjectLung non small cell canceren
dc.subjectDose responseen
dc.subjectConference paperen
dc.subjectPatient selectionen
dc.titlePaclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: A randomized studyen
dc.description.issue4 SUPPL.12en
dc.description.endingpageS1233Ιατρική Σχολή / Medical SchoolΙατρική Σχολή / Medical School
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record